Wyss InstituteBioinspired Therapeutics & Diagnostics – Wyss Institute

David Walt named as laureate for National Medal of Technology and Innovation

Jessica Leff — Tue, 07 Jan 2025 14:52:56 +0000

By Benjamin Boettner (BOSTON) — On January 3, Wyss Institute Core Faculty member David Walt, Ph.D., who also is a Professor of Pathology at Boston’s Brigham and Women’s Hospital (BWH), the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School (HMS), an Associate member at the Broad Institute, and a Howard Hughes Medical Institute Professor…

Source

Collaborative asthma project between Brigham and Women’s Hospital and the Wyss Institute advances with new grant support

Jessica Leff — Mon, 16 Dec 2024 15:55:41 +0000

By Benjamin Boettner (BOSTON) – Asthma affects more than 260M people worldwide and nearly 28M people in the U.S. alone, where, on average, 10 people die from attacks of the chronic disease each day. Many of these deaths could be prevented if patients had timely access to the appropriate therapy following an accurate diagnosis. Driven by an acute sense of urgency to close this diagnostic gap…

Source

Wyss Institute’s iNodes team receives ARPA-H Sprint for Women’s Health award to advance the first implantable immune organs to treat ovarian cancer

Jessica Leff — Tue, 12 Nov 2024 14:58:41 +0000

By Benjamin Boettner (BOSTON) — Ovarian cancer is more deadly than any other type of female reproductive organ cancer. It is estimated that in 2024, in the U.S. alone, more than 12,000 women will die from the disease because available therapies are not effective. To help overcome this striking deficit in women’s health, ARPA-H has selected a team at the Wyss Institute at Harvard University as…

Source

Closing in on Parkinson’s Disease proteins in extracellular vesicles in the blood

Jessica Leff — Fri, 01 Nov 2024 13:20:38 +0000

By Benjamin Boettner (BOSTON) — Brain disorders like Parkinson’s (PD) or Alzheimer’s Disease (AD) start to develop in patients much earlier than when their first clinical symptoms appear. Treating patients at these early stages could slow or even stop their disease, but there is currently no way to diagnose brain disorders at those pre-symptomatic stages. Thus far, the specific brain lesions…

Source

“Suspended animation” drug could aid organ transplantation and survival from traumatic injury

Jessica Leff — Tue, 24 Sep 2024 14:50:33 +0000

(CAMBRIDGE, UK) – Researchers have shown that a non-addictive pain relief drug could be used to preserve cells and organs quickly and safely for transplantation, removing the need for static cold storage. The research, published today in eLife, was described by the editors as an important study providing solid evidence that the existing drug, SNC80, can rapidly and reversibly slow biochemical…

Source

Eliz Amar Lewis on Using Many Tools to Fight a Sophisticated Disease

Jessica Leff — Tue, 24 Sep 2024 14:50:19 +0000

The Humans of the Wyss (HOW) series features members of the Wyss community discussing their work, the influences that shape them as professionals, and their collaborations at the Wyss Institute and beyond. Eliz Amar Lewis has always been fascinated by biology. But when she saw her grandmother bravely battle breast cancer, she was inspired to use her passion to develop a smart and sophisticated…

Source

Preventing pollution with bioinspired solutions

Jessica Leff — Tue, 17 Sep 2024 21:14:47 +0000

By Lindsay Brownell In honor of Pollution Prevention Week, we’re highlighting three Wyss projects that are taking on the formidable problems of PFAS and plastic – persistent and toxic pollutants that threaten the health of humans, animals, and ecosystems. Per- and polyfluoroalkyl substances (PFAS), or “forever chemicals,” are toxic substances that increase the risk of many health…

Source

Wyss Institute team selected by DARPA-SHIELD program to develop first-of-its-kind biologically engineered broad-spectrum antimicrobial therapeutic

Jessica Leff — Mon, 16 Sep 2024 13:25:50 +0000

By Benjamin Boettner (BOSTON) — Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University received a contract for up to $12M from the Defense Advanced Research Projects Agency (DARPA)’s new SHIELD program. The SHIELD (Synthetic Hemo-technologies to Locate and Disinfect) program aims to develop a prophylactic treatment that can be broadly administered to…

Source

Ropirio: Novel Treatments Targeting the Lymphatic System

Mariel Schoen — Wed, 11 Sep 2024 13:56:37 +0000

The human lymphatic system is vast and critical to our health, including the proper functioning of our immune system. Over the last decade, research into the lymph system has revealed its dysfunction in a wide variety of diseases, but development of drugs to directly target the lymph system has lagged, in part because there are few reliable preclinical models of lymph vessels on which to test drug…

Source

Ropirio launches from Wyss Institute to develop first-in-class lymphatic medicines

Mariel Schoen — Wed, 11 Sep 2024 13:55:12 +0000

By Lindsay Brownell (BOSTON) — The Wyss Institute at Harvard University announced today that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard’s Office of Technology Development (OTD) and Boston University (BU)’s Technology Development office for novel molecules that activate the lymphatic system – a first in the pharma industry. “There has been a…

Source